Brenner, A. J., Cohen, Y. C., Vredenburgh, J. J., Peters, K. B., Nayak, L., Blumenthal, D. T., … Wen, P. Y. (2016). Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial. In Journal of Clinical Oncology (Vol. 34, pp. 2074–2074). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.2074

Brenner, Andrew Jacob, Yael Chava Cohen, James J. Vredenburgh, Katherine B. Peters, Lakshmi Nayak, Deborah T. Blumenthal, Felix Bokstein, et al. “Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.” In Journal of Clinical Oncology, 34:2074–2074. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2074.

Brenner AJ, Cohen YC, Vredenburgh JJ, Peters KB, Nayak L, Blumenthal DT, et al. Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 2074–2074.

Brenner, Andrew Jacob, et al. “Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 2074–2074. Crossref, doi:10.1200/jco.2016.34.15_suppl.2074.

Brenner AJ, Cohen YC, Vredenburgh JJ, Peters KB, Nayak L, Blumenthal DT, Bokstein F, Breitbart E, Bangio L, Sher N, Leubitz AR, Yust-Katz S, Peretz I, Freedman LS, Olmer L, Wen PY. Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 2074–2074.